Back to Search Start Over

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

Authors :
Schaeffer E
Srinivas S
Antonarakis ES
Armstrong AJ
Bekelman JE
Cheng H
D'Amico AV
Davis BJ
Desai N
Dorff T
Eastham JA
Farrington TA
Gao X
Horwitz EM
Ippolito JE
Kuettel MR
Lang JM
McKay R
McKenney J
Netto G
Penson DF
Pow-Sang JM
Reiter R
Richey S
Roach Iii M
Rosenfeld S
Shabsigh A
Spratt DE
Teply BA
Tward J
Shead DA
Freedman-Cass DA
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2021 Feb 02; Vol. 19 (2), pp. 134-143. Date of Electronic Publication: 2021 Feb 02.
Publication Year :
2021

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

Details

Language :
English
ISSN :
1540-1413
Volume :
19
Issue :
2
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
33545689
Full Text :
https://doi.org/10.6004/jnccn.2021.0008